

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/532,041 Confirmation No. : 5818
First Named Inventor : Francois Schutze, et al.
Filed : June 23, 2006
TC/A.U. : 1617
Examiner : Carlie K. Huynh

Docket No. : 099380.0000121
Customer No. : 23911

Title : Pharmaceutical Composition Combining Tenatoprazole and an Anti-Inflammatory Agent

RESPONSE TO ELECTION REQUIREMENT

Mail Stop AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In complete response to the Office Action mailed November 6, 2007, Applicants submit herewith a three month extension of time, extending the period of response from December 6, 2007 to March 6, 2008, and the following response.

In the Office Action, the Examiner sets forth an election of species requirement. As such, the Examiner is requiring election of a species of an anti-inflammatory agent selected from aspirin, diclofenac, etodolac, indometacin, naproxen, ibuprofen, piroxicam, rofecoxib, or celecoxib.


Applicants hereby elect celecoxib as the anti-inflammatory agent for the purposes of searching only. It is believed that claims 1, 2, 5, 6-9, 11, 14, 15, and 18-21 read on the elected species.

Applicants expressly reserve the right to file one or more divisional or continuation applications if necessary.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #099380.0000121.)

Respectfully submitted,

March 6, 2008



Melissa M. Hayworth
Registration No. 45,774

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
MMH/lk
099380-0000121